Australia - engelsk - Department of Health (Therapeutic Goods Administration)

southern xp ip pty ltd - cefuroxime sodium, quantity: 788.9 mg (equivalent: cefuroxime, qty 750 mg) - injection, powder for - excipient ingredients: - cefuroxime sxp is indicated in adults and children of 40 kg or greater in weight for the prevention of infections associated with certain surgical procedures of the gastrointestinal (including oesophageal), orthopaedic, cardiovascular and gynaecological systems (including caesarean section) (see section 4.4: special warnings and precautions for use and section 5.2: pharmacokinetic properties).,in the prevention of infections in which it is very likely that anaerobic organisms will be encountered, cefuroxime should be administered with additional appropriate antibacterial agents such as metronidazole.,consideration should be given to official guidance on the appropriate use of antibacterial agents, as antibiotic prophylaxis is not required in all gastrointestinal, orthopaedic, cardiovascular and gynaecological procedures or surgeries.,for patients with specific cardiac conditions which predispose them to endocarditis who are undergoing abdominal surgery for which surgical antibiotic prophylaxis is indicated, the prophylaxis regimen should additionally include an antibiotic active against enterococci.,for patients undergoing orthopedic or cardiovascular surgery known to be, or at risk of being, colonised or infected with methicillin-resistant s. aureus (mrsa), add an antibiotic with activity against mrsa, such as vancomycin.,cefuroxime sxp is not indicated in children less than 40 kg in weight.

Frankrike - fransk - ANSM (Agence Nationale de Sécurité du Médicament et des Produits de Santé)

eugia pharma (malta) ltd - céfuroxime 50 mg sous forme de : céfuroxime sodique - poudre - pour un flacon > céfuroxime 50 mg sous forme de : céfuroxime sodique - organes sensoriels – médicaments ophtalmologiques – anti-infectieux – antibiotiques - classe pharmacothérapeutique organes sensoriels – médicaments ophtalmologiques – anti-infectieux – antibiotiques, - code atc : s01aa27cefuroxime arrow 50 mg, poudre pour solution injectable contient une substance active, la céfuroxime (sous forme de céfuroxime sodique) qui appartient au groupe d’antibiotiques appelé céphalosporines. les antibiotiques sont utilisés pour tuer les bactéries ou « germes » causant les infections.ce médicament sera utilisé si vous allez subir une intervention chirurgicale de l’œil pour cataracte (opacification du cristallin).votre chirurgien ophtalmologiste vous administrera ce médicament par injection dans l’œil à la fin de l’intervention chirurgicale de la cataracte, afin de prévenir une infection de l’œil

USA - engelsk - NLM (National Library of Medicine)

lupin pharmaceuticals, inc. - cefuroxime axetil (unii: z49qdt0j8z) (cefuroxime - unii:o1r9fj93ed) - cefuroxime 250 mg - cefuroxime axetil tablets are indicated for the treatment of adult patients and pediatric patients (13 years and older) with mild-to-moderate pharyngitis/tonsillitis caused by susceptible strains of streptococcus pyogenes. limitations of use - the efficacy of cefuroxime axetil in the prevention of rheumatic fever was not established in clinical trials. - the efficacy of cefuroxime axetil in the treatment of penicillin-resistant strains of streptococcus pyogenes has not been demonstrated in clinical trials. cefuroxime axetil tablets are indicated for the treatment of pediatric patients (who can swallow tablets whole) with acute bacterial otitis media caused by susceptible strains of streptococcus pneumoniae , haemophilus influenzae (including β-lactamase–producing strains), moraxella catarrhalis (including β-lactamase–producing strains), or streptococcus pyogenes . cefuroxime axetil tablets are indicated for the treatment of adult and pediatric patients (13 years and older) with mild-to-moderate acute bacterial maxillary sinusitis caused by susceptible strains of streptococcus pneumoniae or haemophilus influenzae (non-β-lactamase–producing strains only). limitations of use the effectiveness of cefuroxime axetil for sinus infections caused by β-lactamase–producing haemophilus influenzae or moraxella catarrhalis in patients with acute bacterial maxillary sinusitis was not established due to insufficient numbers of these isolates in the clinical trials [see clinical studies (14.1)] . cefuroxime axetil tablets are indicated for the treatment of adult patients and pediatric patients (aged 13 and older) with mild-to-moderate acute bacterial exacerbations of chronic bronchitis caused by susceptible strains of streptococcus pneumoniae , haemophilus influenzae (β-lactamase–negative strains), or haemophilus parainfluenzae (β-lactamase–negative strains). cefuroxime axetil tablets are indicated for the treatment of adult patients and pediatric patients (aged 13 and older) with uncomplicated skin and skin-structure infections caused by susceptible strains of staphylococcus aureus (including β- lactamase–producing strains) or streptococcus pyogenes. cefuroxime axetil tablets are indicated for the treatment of adult patients and pediatric patients (aged 13 and older) with uncomplicated urinary tract infections caused by susceptible strains of escherichia coli or klebsiella pneumoniae . cefuroxime axetil tablets are indicated for the treatment of adult patients and pediatric patients (aged 13 and older) with uncomplicated gonorrhea, urethral and endocervical, caused by penicillinase producing and non-penicillinase–producing susceptible strains of neisseria gonorrhoeae and uncomplicated gonorrhea, rectal, in females, caused by non-penicillinase–producing susceptible strains of neisseria gonorrhoeae . cefuroxime axetil tablets are indicated for the treatment of adult patients and pediatric patients (aged 13 and older) with early lyme disease (erythema migrans) caused by susceptible strains of borrelia burgdorferi. to reduce the development of drug-resistant bacteria and maintain the effectiveness of cefuroxime axetil and other antibacterial drugs, cefuroxime axetil should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. cefuroxime axetil is contraindicated in patients with a known hypersensitivity (e.g., anaphylaxis) to cefuroxime axetil or to other β-lactam antibacterial drugs (e.g., penicillins and cephalosporins). risk summary available data from published epidemiologic studies, case series, and case reports over several decades with cephalosporin use, including cefuroxime axetil, in pregnant women have not established drug-associated risks of major birth defects, miscarriage, or adverse maternal or fetal outcomes (see data) . in studies in pregnant mice and rats administered oral cefuroxime axetil during organogenesis at 14 and 9 times the maximum recommended human dose (mrhd) based on body surface area, respectively, there were no adverse developmental outcomes (see data). the estimated background risk of major birth defects and miscarriage for the indicated populations are unknown. all pregnancies have a background risk of birth defects, loss, or other adverse outcomes. in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. clinical considerations disease-associated maternal and/or embryo/fetal risk: maternal gonorrhea may be associated with preterm birth, low neonatal birth weight, chorioamnionitis, intrauterine growth restriction, small for gestational age, and premature rupture of membranes. perinatal transmission of gonorrhea to the offspring can result in infant blindness, joint infections, and bloodstream infections. data human data: while available studies cannot definitively establish the absence of risk, published data from epidemiologic studies, case series, and case reports over several decades have not identified an association with cephalosporin use (including cefuroxime axetil) during pregnancy and major birth defects, miscarriage, or other adverse maternal or fetal outcomes. available studies have methodologic limitations, including small sample size, retrospective data collection, and inconsistent comparator groups. animal data: studies performed with oral cefuroxime axetil administered to pregnant mice during organogenesis (gestation days 7 through 16) at doses up to 3,200 mg/kg/day (14 times the mrhd based on body surface area); and in rats dosed during organogenesis and lactation (gestation days 7 through 16 and gestation days 17 through lactation day 21, respectively) at doses up to 1,000 mg/kg/day (9 times the mrhd based on body surface area) have revealed no adverse developmental outcomes. risk summary based on several published case reports describing multiple lactating women who received cefuroxime via intravenous, intramuscular, and oral routes, cefuroxime is present in human milk. the highest maternal milk concentration described occurred in lactating women 8 hours after an intramuscular administration of cefuroxime 750 mg. allowing for an infant milk consumption of 150 ml/kg/day, the estimated breastfed infant dose would be less than 1% of the adult dose. no data are available on the effects of the drug on the breastfed infant or the effects of the drug on milk production. the developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for cefuroxime and any potential adverse effects on the breastfed infant from cefuroxime or from the underlying maternal condition. the safety and effectiveness of cefuroxime axetil have been established for pediatric patients aged 3 months to 12 years for acute bacterial maxillary sinusitis based upon its approval in adults. use of cefuroxime axetil in pediatric patients is supported by pharmacokinetic and safety data in adults and pediatric patients, and by clinical and microbiological data from adequate and well-controlled trials of the treatment of acute bacterial maxillary sinusitis in adults and of acute otitis media with effusion in pediatric patients. it is also supported by postmarketing adverse events surveillance. [see indications and usage (1), dosage and administration (2), adverse reactions (6), clinical pharmacology (12.3)]. of the total number of subjects who received cefuroxime axetil in 20 clinical trials, 375 were aged 65 and older while 151 were aged 75 and older. no overall differences in safety or effectiveness were observed between these subjects and younger adult subjects. reported clinical experience has not identified differences in responses between the elderly and younger adult patients, but greater sensitivity of some older individuals cannot be ruled out. cefuroxime is substantially excreted by the kidney, and the risk of adverse reactions may be greater in patients with impaired renal function. because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function. reducing the dosage of cefuroxime axetil is recommended for adult patients with severe renal impairment (creatinine clearance <30 ml/min) [see dosage and administration (2.5), clinical pharmacology (12.3)] .

Canada - fransk - Health Canada

teva canada limited - céfuroxime (céfuroxime axétil) - comprimé - 250mg - céfuroxime (céfuroxime axétil) 250mg - second generation cephalosporins

Canada - fransk - Health Canada

teva canada limited - céfuroxime (céfuroxime axétil) - comprimé - 500mg - céfuroxime (céfuroxime axétil) 500mg - second generation cephalosporins

Canada - fransk - Health Canada

pro doc limitee - céfuroxime (céfuroxime axétil) - comprimé - 500mg - céfuroxime (céfuroxime axétil) 500mg - second generation cephalosporins

USA - engelsk - NLM (National Library of Medicine)

direct rx - cefuroxime axetil (unii: z49qdt0j8z) (cefuroxime - unii:o1r9fj93ed) - cefuroxime 250 mg - to reduce the development of drug-resistant bacteria and maintain the effectiveness of cefuroxime axetil and other antibacterial drugs, cefuroxime axetil should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. note: cefuroxime axetil tablets and cefuroxime axetil for oral suspension are not bio­equivalent and are not substitutable on a milligram-per-milligram basis (see clinical pharmacology). cefuroxime axetil tablets cefuroxime axetil tablets are indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms in the conditions listed below:   - pharyngitis/tonsillitis caused by streptococcus pyoge

USA - engelsk - NLM (National Library of Medicine)

physicians total care, inc. - cefuroxime axetil (unii: z49qdt0j8z) (cefuroxime - unii:o1r9fj93ed) - cefuroxime axetil 250 mg - to reduce the development of drug-resistant bacteria and maintain the effectiveness of cefuroxime axetil and other antibacterial drugs, cefuroxime axetil should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.   note: cefuroxime axetil tablets and cefuroxime axetil for oral suspension are not bio­equivalent and are not substitutable on a milligram-per-milligram basis (see clinical pharmacology).   cefuroxime axetil tablets: cefuroxime axetil tablets are indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms in the conditions listed below:   1.    pharyngitis/tonsillitis caused

USA - engelsk - NLM (National Library of Medicine)

rebel distributors corp - cefuroxime axetil (unii: z49qdt0j8z) (cefuroxime - unii:o1r9fj93ed) - cefuroxime axetil 250 mg - to reduce the development of drug-resistant bacteria and maintain the effectiveness of cefuroxime axetil and other antibacterial drugs, cefuroxime axetil should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.   note: cefuroxime axetil tablets and cefuroxime axetil for oral suspension are not bio­equivalent and are not substitutable on a milligram-per-milligram basis (see clinical pharmacology).   cefuroxime axetil tablets: cefuroxime axetil tablets are indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms in the conditions listed below:   1.    pharyngitis/tonsillitis caused by streptococcus pyogenes.

Frankrike - fransk - ANSM (Agence Nationale de Sécurité du Médicament et des Produits de Santé)

laboratoires saint germain - société civile de recherche - céfuroxime 125 mg sous forme de : céfuroxime axétil 150 - comprimé - 125 mg - pour un comprimé > céfuroxime 125 mg sous forme de : céfuroxime axétil 150,36 mg - antibactériens pour usage systémique - classe pharmacothérapeutique : antibactériens pour usage systémique, céphalosporines de deuxième génération, code atc : j01dc02cefuroxime biogaran est un antibiotique utilisé chez l’adulte et l’enfant. il agit en détruisant les bactéries responsables d’infections. il appartient à une famille de médicaments appelés céphalosporines.indications thérapeutiquescefuroxime biogaran est utilisé pour traiter les infections : de la gorge des sinus de l'oreille moyenne des poumons ou des bronches des voies urinaires de la peau et des tissus mouscefuroxime biogaran peut également être utilisé : pour traiter la maladie de lyme (une infection transmise par des parasites appelés tiques)votre médecin pourra effectuer des tests afin d’identifier le type de bactérie responsable de votre infection et contrôler pendant votre traitement si la bactérie est sensible à cefuroxime biogaran.